Jump to Main Content
Tumor homing peptide modified liposomes of capecitabine for improved apoptotic activity and HER2 targeted therapy in breast cancer: in vitro studies
- Singh, Mantosh Kumar, Pindiprolu, Sai Kiran S. S., Reddy Sanapalli, Bharat Kumar, Yele, Vidyasrilekha, Ganesh, G. N. K.
- RSC advances 2019 v.9 no.43 pp. 24987-24994
- Western blotting, antineoplastic activity, apoptosis, bioavailability, breast neoplasms, cytotoxicity, in vitro studies, neoplasm cells, oligopeptides, pro-apoptotic proteins, therapeutics
- In the present study, we have formulated a liposomal formulation of cytotoxic agent capecitabine (CAP) to overcome its bioavailability issues. Then we have surface modified CAP loaded liposomes (CAP-LPs) with a tumour homing peptide (THP-CAP-LPs) to achieve site specific delivery to breast cancer cells. We found a significant cellular internalization of THP-CAP-LPs when compared to unmodified CAP-LPs. The cytotoxic effect of CAP was also significantly improved with THP-CAP-LPs by downregulating anti-apoptotic proteins and upregulating pro-apoptotic proteins as observed by Western blot analysis. THP-CAP-LPs mediated delivery of CAP can be, therefore, a promising approach for improving antitumor activity and reducing off-target effects.